| 产品描述: | Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes. |
| 体外研究: |
Icovamenib 可增强动物糖尿病模型中的血糖控制。 |
| 体内研究: |
Icovamenib 以浓度和葡萄糖依赖的方式促进体外人胰岛培养中β细胞的选择性和受控增殖,并改善β细胞功能。 Icovamenib 对各种脑膜依赖性急性髓系白血病 (AML) 细胞表现出强效细胞毒性。 |
| 参考文献: |
1. Thomas Butler, et al. Irreversible inhibitors of menin-mll interaction.WO2020142557 A1. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.765 ml |
8.824 ml |
17.648 ml |
| 5 mM |
0.353 ml |
1.765 ml |
3.53 ml |
| 10 mM |
0.176 ml |
0.882 ml |
1.765 ml |
| 50 mM |
0.035 ml |
0.176 ml |
0.353 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |